HONG KONG, SHANGHAI & FLORHAM PARK, NJ - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13) has appointed Cavendish Capital Markets Limited as its joint corporate broker in London, effective January 1, 2025. The company, which specializes in biopharmaceuticals, announced this addition to its brokerage network today, stating that Panmure Liberum Limited and HSBC Bank plc will maintain their roles as joint corporate brokers. Panmure Liberum Limited will also continue as Hutchmed's Nominated Advisor for the AIM rules.
Hutchmed is known for its focus on developing targeted therapies and immunotherapies for cancer and immunological diseases. With a portfolio that includes marketed medicines in China and one approved in the US, Europe, and Japan, Hutchmed has established a global presence in the pharmaceutical industry.
The collaboration with Cavendish is expected to support Hutchmed's strategic growth and enhance its visibility in the London financial market. This partnership aligns with the company's ongoing efforts to broaden its investor base and strengthen its position within the biopharmaceutical sector.
The information about this new appointment is based on a press release statement and reflects Hutchmed's continued commitment to expanding its operations and pursuing advancements in medical treatments on a global scale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.